



Recent Scientific Development of Poliovirus Vaccines

Guest Editor:

Prof. Dr. Lester M. Shulman

1. Retired, Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel

2. Laboratory of Environmental Virology, Retired, Central Virology Laboratory, Public Health Services Israel Ministry of Health Sheba Medical Center, Tel Hashomer 52621, Israel

Deadline for manuscript submissions:
closed (31 January 2026)

Message from the Guest Editor

Dear Colleagues,

In 1988, the World Health Assembly established the Global Polio Eradication Initiative, an international effort to terminate all transmissions of wild poliovirus by 2000. Eradication requires (1) effective means to prevent poliovirus infections and/or transmissions and (2) effective surveillance programs to identify poliovirus infections and evaluate the effectiveness of interventions in individuals and/or in unidentified persons within populations.

Many stakeholders have been involved in developing and improving the two main types of vaccines in current use, inactivated (IPV) and live attenuated (OPV) vaccines. However, the ideal polio vaccine, “effective in any outbreak scenario, protect[ing] all vaccinees with one dose, spread[ing] to and protect the unvaccinated population, and have[ing] no detrimental effect” is yet to be developed.

This Special Issue of *Vaccines* focuses on recent scientific advancements achieved from the development and field testing of improved, more genetically stable, oral polio vaccines as well as from current research on alternative vaccines and vaccination strategies.

Prof. Dr. Lester M. Shulman

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)